
Cardiol., 2004, 43:13S-24S; Rosenzweig, Expert Opin. Emerging Drugs, 2006, 11:609-619; McLaughlin *et al.*, Circulation, 2006, 114:1417-1431; Rosenkranz, Clin. Res. Cardiol., 2007, 96:527-541; Driscoll *et al.*, Expert Opin. Pharmacother., 2008, 9:65-81.)

Trepostinil and iloprost are FDA-approved analogs of prostacyclin which, like prostacyclin, are not orally-active. Beraprost is an orally-active analog of prostacyclin approved for the treatment of PAH in Japan, but it has failed registration for the treatment of PAH in Europe and in the US. Of the three FDA-approved drugs, prostacyclin is the best studied in PAH patients. The approximate annual cost of treating PAH with these drugs is $25,000 to $200,000 depending on the dose. At present, many experts consider intravenous prostacyclin to be the most reliable agent for managing the sickest PAH patients. Due to the short half-life of prostacyclin, intravenous treatment is complicated by the need for a continuous infusion. Patients are at risk for potentially fatal rebound pulmonary hypertension if the infusion is abruptly disrupted, as well as significant risk of catheter-related complications including sepsis. (See, *e.g.*, Rosenzweig, Expert Opin. Emerging Drugs, 2006, 11:609-619; Naeije *et al.*, Expert Opin. Pharmacother., 2007, 8:2247-2265; Strauss *et al.*, Clin. Chest. Med., 2007, 28:127-142; Driscoll *et al.*, Expert Opin. Pharmacother., 2008, 9:65-81.)

There is considerable interest in developing prostacyclin analogs (*i.e.*, agonists of the PGI2 receptor) for use in the treatment of other diseases, such as atherothrombosis. Developing stable, orally-active analogs of prostacyclin (*i.e.*, stable, orally-active agonists of the PGI2 receptor) is a rate-limiting step in achieving this goal (see, *e.g.*, Arehart *et al.*, Curr. Med. Chem., 2007, 14:2161-2169; Arehart *et al.*, Circ. Res., 2008, 102(8), 986-93, as well as in the improved management of PAH.

SUMMARY

One aspect of the present invention encompasses a compound selected from compounds of Formula **Ia** and pharmaceutically acceptable salts, solvates and hydrates thereof:



Ia

wherein:

R^1 is selected from: H and C_1-C_6 alkyl;

and

R^2, R^3, and R^4 are each independently selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl, C_3-C_7 cycloalkyl

and heteroaryl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl, C_3-C_7 cycloalkyl and heteroaryl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl, amino, carboxamide, cyano, C_1-C_6 haloalkyl, halogen and hydroxy;

or

R^2 and R^3 together with the pyrazole ring to which they are both attached to form a tricyclic heteroaryl; and R^4 is selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl, C_3-C_7 cycloalkyl and heteroaryl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl, C_3-C_7 cycloalkyl and heteroaryl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, amino, aryl, cyano, C_1-C_6 haloalkyl, halogen and hydroxy.

Disclosed are methods for the treatment of a PGI2 receptor mediated disorder in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of PAH in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of idiopathic PAH in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of familial PAH in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of PAH associated with a collagen vascular disease in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of PAH associated with a collagen vascular disease selected from: scleroderma, CREST syndrome,

systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis, polymyositis, and dermatomyositis in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of PAH associated with a congenital heart disease in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of PAH associated with a congenital heart disease selected from: atrial septic defect (ASD), ventricular septic defect (VSD) and patent ductus arteriosus in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of PAH associated with portal hypertension in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of PAH associated with HIV infection in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of PAH associated with ingestion of a drug or toxin in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of PAH associated with hereditary hemorrhagic telangiectasia in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of PAH associated with splenectomy in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of PAH associated with significant venous or capillary involvement in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of PAH associated with pulmonary veno-occlusive disease (PVOD) in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of PAH associated with pulmonary capillary hemangiomatosis (PCH) in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of platelet aggregation in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of: coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, ischemia-reperfusion injury, restenosis or atrial fibrillation in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of blood clot formation in an angioplasty or coronary bypass surgery individual comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of blood clot formation in an individual suffering from atrial fibrillation comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of atherosclerosis in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of atherothrombosis in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of asthma in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of a symptom of asthma in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of a diabetic-related disorder in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of diabetic peripheral neuropathy in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of diabetic nephropathy in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of diabetic retinopathy in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of glaucoma or other disease of the eye with abnormal intraocular pressure in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of hypertension in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of hypertension intended to confer protection against cerebral ischemia in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of inflammation in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of an inflammatory disease in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of an inflammatory disease selected from: psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus (SLE), ulcerative colitis, ischemia-reperfusion injury, restenosis, atherosclerosis, acne, type 1 diabetes, type 2 diabetes, sepsis, chronic obstructive pulmonary disorder (COPD) and asthma in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods of modulating the activity of a PGI2 receptor by contacting the receptor with a compound of the present disclosure.

Disclosed are methods of agonizing a PGI2 receptor by contacting the receptor with a compound of the present disclosure.

Disclosed are methods for the treatment of PAH selected from: idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease selected from: scleroderma, CREST syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis, polymyositis, and dermatomyositis; PAH associated with a congenital heart disease selected from: atrial septic defect (ASD), ventricular septic defect (VSD) and patent ductus arteriosus in an individual; PAH associated with portal hypertension; PAH associated with HIV infection; PAH associated with ingestion of a drug or toxin; PAH associated with hereditary hemorrhagic telangiectasia; PAH associated with splenectomy; PAH associated with significant venous or capillary involvement; PAH associated with pulmonary veno-occlusive disease (PVOD); and PAH associated with pulmonary capillary hemangiomatosis (PCH) in an individual comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

Disclosed are methods for the treatment of a disorder selected from: platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, ischemia-reperfusion injury, restenosis, atrial fibrillation, blood clot formation, atherosclerosis, atherothrombosis, asthma, a symptom of asthma, a diabetic-related disorder, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, glaucoma or other disease of the eye with abnormal intraocular pressure, hypertension, inflammation, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus (SLE), ulcerative colitis, ischemia-reperfusion injury, restenosis, atherosclerosis, acne, type 1 diabetes, type 2 diabetes, sepsis and

chronic obstructive pulmonary disorder (COPD) in an individual comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition thereof.

One aspect of the present invention pertains to the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of a PGI2 receptor mediated disorder.

One aspect of the present invention pertains to the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of pulmonary arterial hypertension (PAH).

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of idiopathic PAH.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of familial PAH.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of PAH associated with collagen vascular disease.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of PAH associated with a collagen vascular disease selected from: scleroderma, CREST syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis, polymyositis, and dermatomyositis.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of PAH associated with a congenital heart disease.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of PAH associated with a congenital heart disease selected from: atrial septic defect (ASD), ventricular septic defect (VSD) and patent ductus arteriosus.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of PAH associated with portal hypertension.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of PAH associated with HIV infection.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of PAH associated with ingestion of a drug or toxin.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of PAH associated with hereditary hemorrhagic telangiectasia.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of PAH associated with splenectomy.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of PAH associated with significant venous or capillary involvement.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of PAH associated with pulmonary veno-occlusive disease (PVOD).

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of PAH associated with pulmonary capillary hemangiomatosis (PCH).

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of platelet aggregation.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of a PGI2 receptor mediated disorder selected from: coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, ischemia-reperfusion injury, restenosis and atrial fibrillation.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of blood clot formation in an angioplasty or coronary bypass surgery individual.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of blood clot formation in an individual suffering from atrial fibrillation.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of atherosclerosis.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of atherothrombosis.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of asthma.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of a symptom of asthma.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of a diabetic-related disorder.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of diabetic peripheral neuropathy.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of diabetic nephropathy.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of diabetic retinopathy.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of glaucoma or other disease of the eye with abnormal intraocular pressure.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of hypertension.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of hypertension intended to confer protection against cerebral ischemia.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of inflammation.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of an inflammatory disease.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of an inflammatory disease selected from: psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus (SLE), ulcerative colitis, ischemia-reperfusion injury, restenosis, atherosclerosis, acne, type 1 diabetes, type 2 diabetes, sepsis, chronic obstructive pulmonary disorder (COPD) and asthma.

One aspect of the present invention pertains to the use of a compound of the present disclosure in the manufacture of a medicament for modulating the activity of a PGI2 receptor.

One aspect of the present invention pertains to the use of a compound of the present disclosure in the manufacture of a medicament for agonizing a PGI2 receptor.

Disclosed is the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of PAH selected from: idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease selected from: scleroderma, CREST syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis, polymyositis, and dermatomyositis; PAH associated with a congenital heart disease selected from: atrial septic defect (ASD), ventricular septic defect (VSD) and patent ductus arteriosus in an individual; PAH associated with portal hypertension; PAH associated with HIV infection; PAH associated with ingestion of a drug or toxin; PAH associated with

hereditary hemorrhagic telangiectasia; PAH associated with splenectomy; PAH associated with significant venous or capillary involvement; PAH associated with pulmonary veno-occlusive disease (PVOD); and PAH associated with pulmonary capillary hemangiomatosis (PCH).

One aspect of the present invention pertains to the use of a compound of the present disclosure in the manufacture of a medicament for the treatment of a disorder selected from: platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, ischemia-reperfusion injury, restenosis, atrial fibrillation, blood clot formation, atherosclerosis, atherothrombosis, asthma, a symptom of asthma, a diabetic-related disorder, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, glaucoma or other disease of the eye with abnormal intraocular pressure, hypertension, inflammation, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus (SLE), ulcerative colitis, ischemia-reperfusion injury, restenosis, atherosclerosis, acne, type 1 diabetes, type 2 diabetes, sepsis and chronic obstructive pulmonary disorder (COPD).

One aspect of the present invention pertains to compounds of the present disclosure or a pharmaceutical composition of the present disclosure, for use in a method of treatment of the human or animal body by therapy.

One aspect of the present invention pertains to compounds of the present disclosure or a pharmaceutical composition of the present disclosure, for use in a method of treatment of a PGI2 receptor mediated disorder.

One aspect of the present invention pertains to compounds of the present disclosure or a pharmaceutical composition of the present disclosure, for use in a method of treatment of pulmonary arterial hypertension (PAH).

Disclosed are compounds of the present disclosure for use in a method of treatment of idiopathic PAH.

Disclosed are compounds of the present disclosure for use in a method of treatment of familial PAH

Disclosed are compounds of the present disclosure for use in a method of treatment of PAH associated with a collagen vascular disease.

Disclosed are compounds of the present disclosure for use in a method of treatment of PAH associated with a collagen vascular disease selected from: scleroderma, CREST syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis, polymyositis, and dermatomyositis.

Disclosed are compounds of the present disclosure for use in a method of treatment of PAH associated with a congenital heart disease.

Disclosed are compounds of the present disclosure for use in a method of treatment of PAH associated with a congenital heart disease selected from: atrial septic defect (ASD), ventricular septic defect (VSD) and patent ductus arteriosus.

Disclosed are compounds of the present disclosure for use in a method of treatment of PAH associated with portal hypertension.

Disclosed are compounds of the present disclosure for use in a method of treatment of PAH associated with HIV infection.

Disclosed are compounds of the present disclosure for use in a method of treatment of PAH associated with ingestion of a drug or toxin.

Disclosed are compounds of the present disclosure for use in a method of treatment of PAH associated with hereditary hemorrhagic telangiectasia.

Disclosed are compounds of the present disclosure for use in a method of treatment of PAH associated with splenectomy.

Disclosed are compounds of the present disclosure for use in a method of treatment of PAH associated with significant venous or capillary involvement.

Disclosed are compounds of the present disclosure for use in a method of treatment of PAH associated with pulmonary veno-occlusive disease (PVOD).

Disclosed are compounds of the present disclosure for use in a method of treatment of PAH associated with pulmonary capillary hemangiomatosis (PCH).

Disclosed are compounds of the present disclosure for use in a method of treatment of platelet aggregation.

Disclosed are compounds of the present disclosure for use in a method of treatment of: coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, ischemia-reperfusion injury, restenosis or atrial fibrillation.

Disclosed are compounds of the present disclosure for use in a method of treatment of blood clot formation in an angioplasty or coronary bypass surgery individual.

Disclosed are compounds of the present disclosure for use in a method of treatment of blood clot formation in an individual suffering from atrial fibrillation.

Disclosed are compounds of the present disclosure for use in a method of treatment of atherosclerosis.

Disclosed are compounds of the present disclosure for use in a method of treatment of atherothrombosis.

Disclosed are compounds of the present disclosure for use in a method of treatment of asthma.

Disclosed are compounds of the present disclosure for use in a method of treatment of a symptom of asthma.

Disclosed are compounds of the present disclosure for use in a method of treatment of a diabetic-related disorder.

Disclosed are compounds of the present disclosure for use in a method of treatment of diabetic peripheral neuropathy.

Disclosed are compounds of the present disclosure for use in a method of treatment of diabetic nephropathy.

Disclosed are compounds of the present disclosure for use in a method of treatment of diabetic retinopathy.

Disclosed are compounds of the present disclosure for use in a method of treatment of glaucoma or other disease of the eye with abnormal intraocular pressure.

Disclosed are compounds of the present disclosure for use in a method of treatment of hypertension.

Disclosed are compounds of the present disclosure for use in a method of treatment of hypertension intended to confer protection against cerebral ischemia.

Disclosed are compounds of the present disclosure for use in a method of treatment of inflammation.

Disclosed are compounds of the present disclosure for use in a method of treatment of an inflammatory disease.

Disclosed are compounds of the present disclosure for use in a method of treatment of an inflammatory disease selected from: psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus (SLE), ulcerative colitis, ischemia-reperfusion injury, restenosis, atherosclerosis, acne, type 1 diabetes, type 2 diabetes, sepsis, chronic obstructive pulmonary disorder (COPD) and asthma.

One aspect of the present invention pertains to compounds of the present disclosure for use in a method of modulating the activity of a PGI2 receptor.

One aspect of the present invention pertains to compounds of the present disclosure for use in a method of agonizing a PGI2 receptor.

Disclosed are compounds of the present disclosure for use in a method of treatment of PAH selected from: idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease selected from: scleroderma, CREST syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis, polymyositis, and dermatomyositis; PAH associated with a congenital heart disease selected from: atrial septic defect (ASD), ventricular septic defect (VSD) and patent ductus arteriosus in an individual; PAH associated with portal hypertension; PAH associated with HIV infection; PAH associated

with ingestion of a drug or toxin; PAH associated with hereditary hemorrhagic telangiectasia; PAH associated with splenectomy; PAH associated with significant venous or capillary involvement; PAH associated with pulmonary veno-occlusive disease (PVOD); and PAH associated with pulmonary capillary hemangiomatosis (PCH).

One aspect of the present invention pertains to compounds of the present disclosure for use in a method of treatment of a disorder selected from: platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, ischemia-reperfusion injury, restenosis, atrial fibrillation, blood clot formation, atherosclerosis, atherothrombosis, asthma, a symptom of asthma, a diabetic-related disorder, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, glaucoma or other disease of the eye with abnormal intraocular pressure, hypertension, inflammation, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus (SLE), ulcerative colitis, ischemia-reperfusion injury, restenosis, atherosclerosis, acne, type 1 diabetes, type 2 diabetes, sepsis and chronic obstructive pulmonary disorder (COPD).

One aspect of the present invention pertains to processes for preparing a composition comprising admixing a compound of the present disclosure and a pharmaceutically acceptable carrier.

These and other aspects of the invention disclosed herein will be set forth in greater detail as the patent disclosure proceeds.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the results of an experiment which measured the ability of Compound **14** to inhibit the right ventricle hypertrophic response to MCT-induced pulmonary arterial hypertension in rat.


Figure 2 shows the results of an experiment which measured the ability of Compound **31** to inhibit the right ventricle hypertrophic response to MCT-induced pulmonary arterial hypertension in rat.

Figure 3 depicts a general method for the preparation of compounds of the present invention. First, cyclohexane-1,4-dicarboxylic acid is esterified and then reduced to give the corresponding diol. The diol is mono-alkylated with *tert*-butyl bromoacetate and the free hydroxyl is activated as a sulfonate ester. Coupling of the sulfonate ester with a pyrazole followed by acid hydrolysis affords compounds of Formula **Ia**.

Figure 4 depicts an alternative general method for the preparation of compounds of the present invention. In this method the sulfonate ester shown in **Figure 3** is reacted in the presence of a base with a pyrazole bearing a halogen at a position equivalent to R^3. The product then undergoes a Suzuki coupling with a boronic acid derivative and then acid hydrolysis affords compounds of Formula **Ia**.

CLAIMS

1. A compound selected from compounds of Formula **Ia** and pharmaceutically acceptable salts, solvates and hydrates thereof:



Ia

wherein:

R^1 is selected from: H and C_1-C_6 alkyl; and

R^2, R^3, and R^4 are each independently selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl, C_3-C_7 cycloalkyl and heteroaryl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl, C_3-C_7 cycloalkyl and heteroaryl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, amino, aryl, carboxamide, cyano, C_1-C_6 haloalkyl, halogen and hydroxy;

or

R^2 and R^3 together with the pyrazole ring to which they are both attached to form a tricyclic heteroaryl; and R^4 is selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl, C_3-C_7 cycloalkyl and heteroaryl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl, C_3-C_7 cycloalkyl and heteroaryl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, amino, aryl, cyano, C_1-C_6 haloalkyl, halogen and hydroxy.

2. A compound according to claim 1, wherein R^1 is H.

3. A compound according to claim 1, wherein R^1 is C_1-C_6 alkyl.

4. A compound according to claim 3, wherein R^1 is methyl.

5. A compound according to any one of claims 1 to 4, wherein R^2, R^3, and R^4 are each independently selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl, C_3-C_7 cycloalkyl and heteroaryl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl, C_3-C_7 cycloalkyl and heteroaryl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, amino, aryl, carboxamide, cyano, C_1-C_6 haloalkyl, halogen and hydroxy.

6. A compound according to any one of claims 1 to 5, wherein R^2, R^3, and R^4 are each independently selected from: H, 2-(methylsulfinyl)ethyl, 2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2-aminoethylthio, 2-amino-2-oxoethoxy, 2-chlorophenyl, 2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl, 2-fluoro-3-methylphenyl, 2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio, 2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl, 3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl, 3-hydroxypropyl, 3-hydroxypropylthio, 3-isopropoxyphenyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl, 5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl, 6-methoxypyridin-3-yl, benzhydryl, cyanomethoxy, cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, furan-2-yl, isopropyl, methyl, methylsulfinyl, methylsulfonyl, methylthio, *m*-tolyl, *n*-propyl, phenyl, *p*-tolyl, thiophen-2-yl, thiophen-3-yl and trifluoromethyl.

7. A compound according to any one of claims 1 to 6, wherein R^2 is selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, amino, carboxamide, cyano, halogen and hydroxy.

8. A compound according to any one of claims 1 to 6, wherein R^2 is selected from: H, 2-(methylsulfinyl)ethyl, 2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl, 2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl, 2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl, 3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy, cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl, methyl, methylsulfinyl, methylsulfonyl, methylthio, *m*-tolyl, *n*-propyl, phenyl, *p*-tolyl and trifluoromethyl.

9. A compound according to any one of claims 1 to 8, wherein R^3 is selected from: C_1-C_6 alkyl, aryl and heteroaryl; wherein said C_1-C_6 alkyl, aryl and heteroaryl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, aryl, cyano, C_1-C_6 haloalkyl, halogen and hydroxy.

10. A compound according to any one of claims 1 to 8, wherein R^3 is selected from: 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl, 2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl, 2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl, 3,4-difluorophenyl, 3-chloro-2-fluorophenyl, 3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl, 3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl, 5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl, 6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, *m*-tolyl, phenyl, *p*-tolyl, thiophen-2-yl and thiophen-3-yl.


11. A compound according to any one of claims 1 to 10, wherein R^4 is selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, carboxamide, cyano, halogen and hydroxy.

12. A compound according to any one of claims 1 to 10, wherein R^4 is selected from: H, 2,3-difluorophenyl, 2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl, 2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl, ethyl, isopropyl, methyl, methylthio, *m*-tolyl, *n*-propyl, phenyl, *p*-tolyl and trifluoromethyl.

13. A compound according to any one of claims 1 to 12, wherein R^2 and R^3 together with the pyrazole ring to which they are both attached to form a tricyclic heteroaryl.

14. A compound according to any one of claims 1 to 12, wherein R^2 and R^3 together with the pyrazole ring to which they are both attached to form 4,5-dihydro-3*H*-benzo[e]indazol-3-yl or indeno[2,1-c]pyrazol-1(8*H*)-yl.

15. A compound according to claim 1, selected from compounds of Formula **Ic** and pharmaceutically acceptable salts, solvates and hydrates thereof:



Ic

wherein:


R^1 is selected from: H and C_1-C_6 alkyl;

R^2 is selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, amino, carboxamide, cyano, halogen and hydroxy;

R^3 is selected from: C_1-C_6 alkyl, aryl and heteroaryl; wherein said C_1-C_6 alkyl, aryl and heteroaryl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, aryl, cyano, C_1-C_6 haloalkyl, halogen and hydroxy; and

R^4 is selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, carboxamide, cyano, halogen and hydroxy.

16. A compound according to claim 1, selected from compounds of Formula **Ic** and pharmaceutically acceptable salts, solvates and hydrates thereof:



Ic

wherein:


R^1 is selected from: H and methyl;

R^2 is selected from: H, 2-(methylsulfinyl)ethyl, 2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl, 2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl, 2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl, 3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy, cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl, methyl, methylsulfinyl, methylsulfonyl, methylthio, *m*-tolyl, *n*-propyl, phenyl, *p*-tolyl and trifluoromethyl;

R^3 is selected from: 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl, 2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl, 2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl, 3,4-difluorophenyl, 3-chloro-2-fluorophenyl, 3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl, 3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl, 5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl, 6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, *m*-tolyl, phenyl, *p*-tolyl, thiophen-2-yl and thiophen-3-yl; and

R^4 is selected from: H, 2,3-difluorophenyl, 2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl, 2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl, ethyl, isopropyl, methyl, methylthio, *m*-tolyl, *n*-propyl, phenyl, *p*-tolyl and trifluoromethyl.

17. A compound according to claim 1, selected from compounds of Formula **Ic** and pharmaceutically acceptable salts, solvates and hydrates thereof:



Ic


wherein:

R^1 is selected from: H and methyl;

R^2 and R^3 together with the pyrazole ring to which they are both attached to form 4,5-dihydro-3*H*-benzo[e]indazol-3-yl or indeno[2,1-c]pyrazol-1(8*H*)-yl; and

R^4 is selected from: H, 2,3-difluorophenyl, 2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl, 2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl, ethyl, isopropyl, methyl, methylthio, *m*-tolyl, *n*-propyl, phenyl, *p*-tolyl and trifluoromethyl.

18. A compound according to claim 1, selected from compounds of Formula **Ig** and pharmaceutically acceptable salts, solvates and hydrates thereof:



Ig


wherein:

R^2 is selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, amino, carboxamide, cyano, halogen and hydroxy;

R^3 is selected from: C_1-C_6 alkyl, aryl and heteroaryl; wherein said C_1-C_6 alkyl, aryl and heteroaryl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, aryl, cyano, C_1-C_6 haloalkyl, halogen and hydroxy; and

R^4 is selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, carboxamide, cyano, halogen and hydroxy.

19. A compound according to claim 1, selected from compounds of Formula **Ig** and pharmaceutically acceptable salts, solvates and hydrates thereof:



Ig


wherein:

R^2 is selected from: H, 2-(methylsulfinyl)ethyl, 2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl, 2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl, 2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl, 3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy, cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl, methyl, methylsulfinyl, methylsulfonyl, methylthio, *m*-tolyl, *n*-propyl, phenyl, *p*-tolyl and trifluoromethyl;

R^3 is selected from: 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl, 2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl, 2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl, 3,4-difluorophenyl, 3-chloro-2-fluorophenyl, 3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl, 3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl, 5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl, 6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, *m*-tolyl, phenyl, *p*-tolyl, thiophen-2-yl and thiophen-3-yl; and

R^4 is selected from: H, 2,3-difluorophenyl, 2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl, 2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl, ethyl, isopropyl, methyl, methylthio, *m*-tolyl, *n*-propyl, phenyl, *p*-tolyl and trifluoromethyl.

20. A compound according to claim 1, selected from compounds of Formula **Ig** and pharmaceutically acceptable salts, solvates and hydrates thereof:




Ig

wherein:

R^2 and R^3 together with the pyrazole ring to which they are both attached to form a tricyclic heteroaryl; and

R^4 is selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, carboxamide, cyano, halogen and hydroxy.

21. A compound according to claim 1, selected from compounds of Formula **Ig** and pharmaceutically acceptable salts, solvates and hydrates thereof:




Ig

wherein:

R^2 and R^3 together with the pyrazole ring to which they are both attached to form 4,5-dihydro-3*H*-benzo[e]indazol-3-yl or indeno[2,1-c]pyrazol-1(8*H*)-yl; and

R^4 is selected from: H, 2,3-difluorophenyl, 2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl, 2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl, ethyl, isopropyl, methyl, methylthio, *m*-tolyl, *n*-propyl, phenyl, *p*-tolyl and trifluoromethyl.

22. A compound according to claim 1, selected from compounds of Formula **Ii** and pharmaceutically acceptable salts, solvates and hydrates thereof:



Ii


wherein:

R^2 is selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylsulfinyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylthio, amino, carboxamide, cyano, halogen and hydroxy;

R^3 is selected from: C_1-C_6 alkyl, aryl and heteroaryl; wherein said C_1-C_6 alkyl, aryl and heteroaryl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, aryl, cyano, C_1-C_6 haloalkyl, halogen and hydroxy; and

R^4 is selected from: H, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl; wherein said C_1-C_6 alkoxy, C_1-C_6 alkyl, C_1-C_6 alkylthio, aryl and C_3-C_7 cycloalkyl are each optionally substituted with one or more groups selected from: C_1-C_6 alkoxy, C_1-C_6 alkyl, carboxamide, cyano, halogen and hydroxy.

23. A compound according to claim 1, selected from compounds of Formula **Ii** and pharmaceutically acceptable salts, solvates and hydrates thereof:



Ii


wherein:

R^2 is selected from: H, 2-(methylsulfinyl)ethyl, 2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl, 2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl, 2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl, 3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy, cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl, methyl, methylsulfinyl, methylsulfonyl, methylthio, *m*-tolyl, *n*-propyl, phenyl, *p*-tolyl and trifluoromethyl;

R^3 is selected from: 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl, 2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl, 2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl, 3,4-difluorophenyl, 3-chloro-2-fluorophenyl, 3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl, 3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl, 5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl, 6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, *m*-tolyl, phenyl, *p*-tolyl, thiophen-2-yl and thiophen-3-yl; and

R^4 is selected from: H, 2,3-difluorophenyl, 2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl, 2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl, ethyl, isopropyl, methyl, methylthio, *m*-tolyl, *n*-propyl, phenyl, *p*-tolyl and trifluoromethyl.

24. A compound according to claim 1, selected from compounds of Formula **Ii** and pharmaceutically acceptable salts, solvates and hydrates thereof:



Ii

wherein:

R^2 and R^3 together with the pyrazole ring to which they are both attached to form 4,5-dihydro-3*H*-benzo[e]indazol-3-yl or indeno[2,1-c]pyrazol-1(8*H*)-yl; and

R^4 is selected from: H, 2,3-difluorophenyl, 2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl, 2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl, ethyl, isopropyl, methyl, methylthio, *m*-tolyl, *n*-propyl, phenyl, *p*-tolyl and trifluoromethyl.

25. A compound according to claim 1 selected from the following compounds and pharmaceutically acceptable salts, solvates and hydrates thereof:

2-(((1*r*,4*r*)-4-((5-(4-fluorophenyl)-3-(methylthio)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*r*,4*r*)-4-((3-(4-fluorophenyl)-5-(methylthio)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*r*,4*r*)-4-((1-phenyl-4,5-dihydro-3*H*-benzo[e]indazol-3-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*r*,4*r*)-4-((3-phenylindeno[2,1-c]pyrazol-1(8*H*)-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*r*,4*r*)-4-((4-(3-methoxyphenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*r*,4*r*)-4-((4-(3-methoxyphenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*r*,4*r*)-4-((3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*r*,4*r*)-4-((4,5-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(4-fluorophenyl)-5-(methylthio)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*r*,4*r*)-4-((5-methyl-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(4-fluorophenyl)-3-(methylthio)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-methoxyphenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-methoxyphenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-methyl-4,5-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-methyl-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-benzhydryl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*r*,4*r*)-4-((4-benzhydryl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-methyl-5-phenyl-4-*m*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,5-difluorophenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(4-chlorophenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(4-fluorophenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-methyl-3-phenyl-4-*m*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(4-fluorophenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(4-chlorophenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,5-difluorophenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-methoxyphenyl)-3-(methylthio)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-methoxyphenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(3-methoxyphenyl)-3-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(3-methoxyphenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(3-fluoro-5-methoxyphenyl)-3-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(3-fluoro-5-methoxyphenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(4-methoxyphenyl)-3-(methylthio)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(4-methoxyphenyl)-5-(methylthio)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(4-methoxyphenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluoro-5-methoxyphenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluorophenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(4-methoxyphenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluoro-5-methoxyphenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-chlorophenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-chlorophenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluorophenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-methyl-3-phenyl-4-*p*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,4-difluorophenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(4-chlorophenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluorophenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(4-fluorophenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chloro-2-fluorophenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,4-difluorophenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chloro-2-fluorophenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-methyl-5-phenyl-4-*p*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chloro-4-fluorophenyl)-3-methyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chloro-4-fluorophenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(4-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-phenyl-4-*m*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-phenyl-4-*p*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-fluorophenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-methyl-4-phenyl-5-*m*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-methyl-4-phenyl-3-*m*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(3-chlorophenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(3-fluorophenyl)-3-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(3-fluorophenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(3-chloro-2-fluorophenyl)-3-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(3-chloro-2-fluorophenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-fluorophenyl)-3-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-fluorophenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2,3-difluorophenyl)-3-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2,3-difluorophenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(methylthio)-4,5-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(methylthio)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,5-difluorophenyl)-3-(methylthio)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,5-difluorophenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(5-cyano-2-fluorophenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3,4-difluorophenyl)-5-ethoxy-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethoxy-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-3-(methylthio)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-isopropoxyphenyl)-3-(methylthio)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-isopropoxyphenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-5-(methylsulfonyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,5-difluorophenyl)-5-(methylsulfonyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(ethylthio)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(ethylthio)-4-(3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(ethylthio)-4-(2-fluoro-3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluorophenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-fluoro-3-methoxyphenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluoro-5-methoxyphenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(4-fluorophenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(methylthio)-3-phenyl-4-(3-(trifluoromethyl)phenyl)-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(4-chlorophenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-ethyl-4-(3-methoxyphenyl)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-4-(3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-ethyl-4,5-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-ethyl-4-(3-fluorophenyl)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-4-(3-fluorophenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-ethyl-4-(2-fluoro-3-methoxyphenyl)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-4-(2-fluoro-3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-3-ethyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-5-ethyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(methylthio)-3-phenyl-4-(thiophen-2-yl)-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(furan-2-yl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(methylthio)-3-phenyl-4-(thiophen-3-yl)-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(methylthio)-4-(5-methylthiophen-2-yl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-isopropyl-4,5-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluorophenyl)-5-isopropyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-methoxyphenyl)-5-(methylsulfinyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-3-ethyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-5-ethyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-5-isopropyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(ethylthio)-4-(2-fluorophenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(ethylthio)-4-(3-fluoro-5-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-cyclopropyl-4-(3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-cyclopropyl-4,5-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-cyclopropyl-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-isopropyl-4-(3-methoxyphenyl)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-3-isopropyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-fluoro-3-methoxyphenyl)-3-isopropyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-cyclopropyl-4-(2-fluoro-3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-cyclopropyl-4-(2,3-difluorophenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-isopropyl-4-(3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-5-isopropyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-fluoro-3-methoxyphenyl)-5-isopropyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

methyl 2-(((1*s*,4*s*)-4-((5-(methylthio)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-3-cyclopropyl-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-5-cyclopropyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluoro-5-methylphenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(5-fluoropyridin-3-yl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

methyl 2-(((1*s*,4*s*)-4-((4-(3-methoxyphenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate;

2-(((1*s*,4*s*)-4-((3-(4-fluorophenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(4-chlorophenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-methyl-4-phenyl-3-*p*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(4-methoxyphenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2,4-difluorophenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-5-(ethylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-fluoro-4-methylphenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(4-chloro-2-fluorophenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-fluoro-4-methoxyphenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-hydroxyethylthio)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(5-fluoropyridin-3-yl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(ethylthio)-4-(5-fluoropyridin-3-yl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-4-(5-fluoropyridin-3-yl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((1-phenyl-4,5-dihydro-3*H*-benzo[e]indazol-3-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3,4-diphenyl-5-(trifluoromethyl)-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-phenyl-4-*p*-tolyl-5-(trifluoromethyl)-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-hydroxyphenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-methoxyphenyl)-5-phenyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-methoxyphenyl)-3-phenyl-5-(trifluoromethyl)-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*R*,4*s*)-4-((3-((*S*)-3,4-dihydroxybutyl)-4,5-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*R*,4*s*)-4-((5-((*S*)-3,4-dihydroxybutyl)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*R*,4*s*)-4-((5-((*S*)-3,4-dihydroxybutyl)-4-(3-fluorophenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*R*,4*s*)-4-((4-(3,4-difluorophenyl)-3-((*S*)-3,4-dihydroxybutyl)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*R*,4*s*)-4-((4-(3,4-difluorophenyl)-5-((*S*)-3,4-dihydroxybutyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*R*,4*s*)-4-((5-((*S*)-3,4-dihydroxybutyl)-4-(3-hydroxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*R*,4*s*)-4-((4-(3-chlorophenyl)-5-((*S*)-3,4-dihydroxybutyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(4-chlorophenyl)-5-ethyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-3-(4-fluorophenyl)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-3-(2-fluoro-4-methoxyphenyl)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-3-(4-methoxyphenyl)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-3-(2-fluoro-4-methylphenyl)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-4-phenyl-3-*p*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*S*,4*s*)-4-((5-((*R*)-3,4-dihydroxybutyl)-4-(3-fluorophenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*S*,4*s*)-4-((4-(3,4-difluorophenyl)-5-((*R*)-3,4-dihydroxybutyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*S*,4*s*)-4-((4-(3-chlorophenyl)-5-((*R*)-3,4-dihydroxybutyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-4-(3-hydroxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-hydroxyphenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(ethylthio)-4-(2-fluoro-3-hydroxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-3-(4-hydroxyphenyl)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(4-chloro-3-fluorophenyl)-5-ethyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(ethylthio)-4-(3-hydroxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-methoxyethyl)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-methoxyethyl)-4-(3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-hydroxyphenyl)-5-(2-methoxyethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-methoxyethyl)-4-(6-methoxypyridin-3-yl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-fluoro-3-hydroxyphenyl)-5-(2-methoxyethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(cyanomethylthio)-4,5-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(cyanomethylthio)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-ethoxyethylthio)-4,5-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-ethoxyethylthio)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(3-hydroxypropylthio)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-methoxyethylthio)-4,5-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-methoxyethylthio)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-5-(2-methoxyethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chloro-2-fluorophenyl)-5-(2-methoxyethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-fluoro-3-methylphenyl)-5-(2-methoxyethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-methoxyethyl)-3-phenyl-4-*m*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluorophenyl)-5-(2-methoxyethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-methoxypyridin-4-yl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-4-(2-methoxypyridin-4-yl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-5-(2-methoxyethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-hydroxyethylthio)-4-(3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-5-(2-hydroxyethylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-hydroxyethylthio)-4-phenyl-3-*p*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-ethyl-4-(5-methoxypyridin-3-yl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-methoxyphenyl)-3-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluorophenyl)-3-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-3-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-phenyl-5-propyl-4-*m*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-fluoro-3-methoxyphenyl)-3-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-3-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chloro-2-fluorophenyl)-3-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-fluoro-3-methylphenyl)-3-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-hydroxyethylthio)-3-phenyl-4-*m*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-fluoro-3-hydroxyphenyl)-3-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluorophenyl)-5-(2-hydroxyethylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-fluoro-3-hydroxyphenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(5-methoxypyridin-3-yl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chloro-2-fluorophenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-(methylthio)ethyl)-3-phenyl-4-*m*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-5-(2-hydroxyethylsulfinyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-fluoro-3-methylphenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chloro-2-fluorophenyl)-5-(2-(methylsulfinyl)ethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-(methylsulfinyl)ethyl)-3-phenyl-4-*m*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-hydroxyphenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluorophenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(4-fluorophenyl)-4-phenyl-3-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(4-fluorophenyl)-4-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(4-chloro-3-fluorophenyl)-4-phenyl-3-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(4-chloro-3-fluorophenyl)-4-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(4-chlorophenyl)-4-phenyl-3-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(4-chlorophenyl)-4-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(3,4-difluorophenyl)-4-phenyl-3-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(3,4-difluorophenyl)-4-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-fluoro-4-methoxyphenyl)-4-phenyl-3-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-fluoro-4-methoxyphenyl)-4-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(4-methoxyphenyl)-4-phenyl-3-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(4-methoxyphenyl)-4-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-fluoro-4-methylphenyl)-4-phenyl-3-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-fluoro-4-methylphenyl)-4-phenyl-5-propyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-(methylthio)ethyl)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-fluoro-4-methylphenyl)-3-(2-methoxyethyl)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-fluoro-4-methylphenyl)-5-(2-methoxyethyl)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-fluoro-4-methylphenyl)-5-(2-methoxyethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2-fluoro-4-methylphenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-methoxyphenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*r*,4*r*)-4-((3-(cyanomethylthio)-4-(3-methoxyphenyl)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(cyanomethylthio)-4-(3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-methoxyethyl)-5-(3-methoxyphenyl)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-methoxyethyl)-3-(3-methoxyphenyl)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chloro-2-fluorophenyl)-5-(2-(methylsulfonyl)ethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-aminoethylthio)-4-phenyl-3-*p*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-hydroxyethyl)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-hydroxyethyl)-4-(3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-5-(2-hydroxyethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluorophenyl)-5-(2-hydroxyethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(4-fluorophenyl)-5-(2-hydroxyethylthio)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(4-fluorophenyl)-3-(2-hydroxyethylthio)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(cyanomethylthio)-4-phenyl-3-*p*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(cyanomethylthio)-3-(4-fluorophenyl)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-cyanoethyl)-4,5-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-cyanoethyl)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-cyanoethyl)-4-(3-methoxyphenyl)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-cyanoethyl)-4-(3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-cyanoethyl)-4-(3-hydroxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-3-(2-cyanoethyl)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-5-(2-cyanoethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-cyanoethyl)-4-(3-fluorophenyl)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-cyanoethyl)-4-(3-fluorophenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-cyanoethyl)-4-(3-hydroxyphenyl)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chloro-2-fluorophenyl)-3-(2-cyanoethyl)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chloro-2-fluorophenyl)-5-(2-cyanoethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(3-hydroxypropyl)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(3-hydroxypropyl)-4-(3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(2,3-difluorophenyl)-5-(3-hydroxypropyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-fluorophenyl)-5-(3-hydroxypropyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-5-(cyanomethylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chloro-2-fluorophenyl)-5-(2-hydroxyethyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*r*,4*r*)-4-((3-(2-amino-2-oxoethoxy)-4-(3-methoxyphenyl)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-amino-2-oxoethoxy)-4-(3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*r*,4*r*)-4-((3-(2-amino-2-oxoethoxy)-4-(2-fluoro-3-methoxyphenyl)-5-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-amino-2-oxoethoxy)-4-(2-fluoro-3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chloro-2-fluorophenyl)-5-(3-hydroxypropyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-5-(3-hydroxypropyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(cyanomethoxy)-4-(3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(3,4-difluorophenyl)-5-ethyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-fluoro-4-methylphenyl)-3-(2-hydroxyethyl)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-fluoro-4-methylphenyl)-3-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-fluoro-4-methylphenyl)-5-(2-hydroxyethyl)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(3-hydroxypropyl)-4-phenyl-3-*p*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(3-hydroxypropyl)-4-phenyl-5-*p*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-(methylsulfonyl)ethyl)-4-phenyl-3-*p*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((3-(2-fluoro-4-methylphenyl)-5-(2-(methylsulfonyl)ethyl)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl) methoxy)acetic acid;

2-(((1*s*,4*s*)-4-((5-(2-hydroxyethyl)-4-phenyl-3- *p*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid; and

2-(((1*s*,4*s*)-4-((1-*p*-tolyl-4,5-dihydro-3*H*-benzo[e]indazol-3-yl)methyl)cyclohexyl)methoxy)acetic acid.

26. A compound according to claim 1, which is:
2-(((1*s*,4*s*)-4-((3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid (compound 3);
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

27. A compound according to claim 1, which is:
2-(((1*s*,4*s*)-4-((4-(3-methoxyphenyl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl) methoxy)acetic acid (compound 14),
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

28. A compound according to claim 1, which is:
2-(((1*s*,4*s*)-4-((4-(3-methoxyphenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl) methoxy)acetic acid (compound 31),
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

29. A compound according to claim 1, which is:
2-(((1*s*,4*s*)-4-((5-(methylthio)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl) methoxy)acetic acid (compound 76),
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

30. A compound according to claim 1, which is:
2-(((1*s*,4*s*)-4-((4-(3-chlorophenyl)-5-(methylthio)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl) methoxy)acetic acid (compound 95),
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

31. A compound according to claim 1, which is:
2-(((1*s*,4*s*)-4-((5-ethyl-4-(3-methoxyphenyl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl) methoxy)acetic acid (compound 99),
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

32. A compound according to claim 1, which is:
2-(((1*s*,4*s*)-4-((5-(methylthio)-4-(5-methylthiophen-2-yl)-3-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl) methoxy)acetic acid (compound 111),
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

33. A compound according to claim 1, which is:
2-(((1*s*,4*s*)-4-((3-(2-fluoro-4-methylphenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl) methoxy)acetic acid (compound 143),
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

34. A compound according to claim 1, which is:
2-(((1*s*,4*s*)-4-((3-(4-chloro-2-fluorophenyl)-5-methyl-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl) methoxy)acetic acid (compound 144),
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

35. A compound according to claim 1, which is:
2-(((1*s*,4*s*)-4-((5-(2-hydroxyethylthio)-3,4-diphenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl) methoxy)acetic acid (compound 146),
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

36. A compound according to claim 1, which is:
2-(((1*s*,4*s*)-4-((5-(2-hydroxyethylthio)-3-phenyl-4-*m*-tolyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid (compound 210),
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

37. A compound according to claim 1, which is:
2-(((1*s*,4*s*)-4-((3-(4-fluorophenyl)-5-(2-hydroxyethylthio)-4-phenyl-1*H*-pyrazol-1-yl)methyl)cyclohexyl) methoxy)acetic acid (compound 255),
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

38. A pharmaceutical composition comprising a compound according to any one of claims 1 to 37 and a pharmaceutically acceptable carrier.

39. A process for preparing a composition comprising admixing a compound according to any one of claims 1 to 37 and a pharmaceutically acceptable carrier.

40. A compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38, for use in a method of treatment of the human or animal body by therapy.

41. A compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38, for use in a method of modulating the activity of a PGI2 receptor.

42. A compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38, for use in a method of agonizing a PGI2 receptor.

43. A compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38, for use in a method of treatment of a PGI2 receptor mediated disorder.

44. A compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38, for use in a method of treatment of pulmonary arterial hypertension (PAH).

45. A compound or pharmaceutical composition according to claim 44, wherein said PAH is selected from:

idiopathic PAH;

familial PAH;

PAH associated with a collagen vascular disease selected from: scleroderma, CREST syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis, polymyositis, and dermatomyositis;

PAH associated with a congenital heart disease selected from: atrial septic defect (ASD), ventricular septic defect (VSD) and patent ductus arteriosus;

PAH associated with portal hypertension;

PAH associated with HIV infection;

PAH associated with ingestion of a drug or toxin;

PAH associated with hereditary hemorrhagic telangiectasia;

PAH associated with splenectomy;

PAH associated with significant venous or capillary involvement;

PAH associated with pulmonary veno-occlusive disease (PVOD); and

PAH associated with pulmonary capillary hemangiomatosis (PCH).

46. A compound according to any one of claims 1 to 376 or a pharmaceutical composition according to claim 38, for use in a method of treatment of a disorder selected from: platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, ischemia-reperfusion injury, restenosis, atrial fibrillation, blood clot formation, atherosclerosis, atherothrombosis, asthma, a symptom of asthma, a diabetic-related disorder, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, glaucoma or other disease of the eye with abnormal intraocular pressure, hypertension, inflammation, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus (SLE), ulcerative colitis, ischemia-reperfusion injury, restenosis, atherosclerosis, acne, type 1 diabetes, type 2 diabetes, sepsis and chronic obstructive pulmonary disorder (COPD).

47. Use of a compound according to any one of claims 1 to 37, in the manufacture of a medicament for modulating the activity of a PGI2 receptor.

48. Use of a compound according to any one of claims 1 to 37, in the manufacture of a medicament for agonizing a PGI2 receptor.

49. Use of a compound according to any one of claims 1 to 37, in the manufacture of a medicament for the treatment of a PGI2 receptor mediated disorder.

50. Use of a compound according to any one of claims 1 to 37, in the manufacture of a medicament for the treatment of pulmonary arterial hypertension (PAH).

51. Use according to claim 50, wherein said PAH is selected from:

idiopathic PAH;

familial PAH;

PAH associated with a collagen vascular disease selected from: scleroderma, CREST syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis, polymyositis, and dermatomyositis;

PAH associated with a congenital heart disease selected from: atrial septic defect (ASD), ventricular septic defect (VSD) and patent ductus arteriosus;

PAH associated with portal hypertension;

PAH associated with HIV infection;

PAH associated with ingestion of a drug or toxin;

PAH associated with hereditary hemorrhagic telangiectasia;

PAH associated with splenectomy;

PAH associated with significant venous or capillary involvement;

PAH associated with pulmonary veno-occlusive disease (PVOD); and

PAH associated with pulmonary capillary hemangiomatosis (PCH).

52. Use of a compound according to any one of claims 1 to 37, in the manufacture of a medicament for the treatment of a disorder selected from: platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, ischemia-reperfusion injury, restenosis, atrial fibrillation, blood clot formation, atherosclerosis, atherothrombosis, asthma, a symptom of asthma, a diabetic-related disorder, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, glaucoma or other disease of the eye with abnormal intraocular pressure, hypertension, inflammation, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus (SLE), ulcerative colitis, ischemia-reperfusion injury, restenosis, atherosclerosis, acne, type 1 diabetes, type 2 diabetes, sepsis and chronic obstructive pulmonary disorder (COPD).